From Name:
From Email:
To Name:
To Email:

Optional Message:


Cheaper sequencing points cancer drug researchers to 'super responders'

from FierceBiotech

As sequencing gets cheaper and scientists begin to unravel the underlying genetic factors in various types of cancer, it is now increasingly possible to find out why once-promising drugs failed in some patient groups but could offer big advances in niche populations. Dr. David Solit, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City, wanted to solve the mystery of why some patients, called "outliers" or "super responders," have strong recoveries or have long-term benefits from cancer drugs that have little to no positive outcomes in most patients. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063